Replimune (REPL) Cash from Operations (2017 - 2026)
Replimune (REPL) posted Cash from Operations of 56161000.0 for Q1 2026, up 14.85% sequentially from 65955000.0 in Q4 2025, and down 4.52% YoY from 58821206.04 in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Cash from Operations (2017 - 2026) Analysis & Trends
Replimune has reported Cash from Operations for 10 years, with the latest figure at 56161000.0 in Q1 2026.
- Quarterly Cash from Operations fell 4.52% year-over-year to 56161000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 280344000.0 (down 45.82% YoY) and the FY2026 annual result came in at 280344000.0, down 45.82% from the prior year.
- Cash from Operations climbed to 56161000.0 in Q1 2026 per REPL's latest filing, from 65955000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 22557000.0 in Q1 2022 and troughed at 81212000.0 in Q3 2025.
- A 5-year average of 47568705.88 and a median of 47123000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations grew 11.36% in 2024, then sank 110.18% in 2025.
- Over 5 years, Cash from Operations stood at 28589000.0 in 2022, then plunged by 64.83% to 47123000.0 in 2023, then declined by 7.62% to 50713000.0 in 2024, then slumped by 30.06% to 65955000.0 in 2025, then gained by 14.85% to 56161000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 56161000.0, 65955000.0, and 81212000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | -75.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -75.73 Mn |
| Mar 31, 2026 | -56.16 Mn |
| Dec 31, 2025 | -65.96 Mn |
| Sep 30, 2025 | -81.21 Mn |
| Jun 30, 2025 | -77.02 Mn |
| Mar 31, 2025 | -53.73 Mn |
| Dec 31, 2024 | -50.71 Mn |
| Sep 30, 2024 | -38.64 Mn |
| Jun 30, 2024 | -49.17 Mn |
| Mar 31, 2024 | -46.17 Mn |
| Dec 31, 2023 | -47.12 Mn |
| Sep 30, 2023 | -43.59 Mn |
| Jun 30, 2023 | -48.59 Mn |
| Mar 31, 2023 | -32.80 Mn |
| Dec 31, 2022 | -28.59 Mn |
| Sep 30, 2022 | -33.21 Mn |
| Jun 30, 2022 | -33.46 Mn |
| Mar 31, 2022 | -22.56 Mn |
| Dec 31, 2021 | -18.35 Mn |
| Sep 30, 2021 | -22.96 Mn |